US Edition
ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer
- Data from the phase 3 DESTINY-Breast09 study, shared at the 2025 ASCO Annual Meeting, demonstrated that combining trastuzumab deruxtecan with pertuzumab significantly improved outcomes in patients with HER2-positive metastatic breast cancer.
- This trial enrolled patients without prior chemotherapy or HER2 therapy for advanced disease, stratified by disease status, hormone receptor, and PIK3CA mutation, with data cutoff on February 26, 2025.
- The open-label, multicenter study randomized 1157 patients into three arms, comparing trastuzumab deruxtecan plus pertuzumab against a taxane-based standard, assessing progression-free survival and safety.
- The median duration of progression-free survival was notably longer at 40.7 months for patients treated with trastuzumab deruxtecan combined with pertuzumab, compared to 26.9 months for those receiving the standard regimen of taxane, trastuzumab, and pertuzumab . Additionally, the progression-free survival rates at 6 months were 93% versus 87.8% for the two groups, respectively.
- These results suggest this combination may become a new first-line standard for metastatic HER2-positive breast cancer, although data remain immature and biomarker guidance is needed for patient selection.
13 Articles
13 Articles
MedPage Today
Anti-Aging, Acupuncture and Health NewsADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer
(MedPage Today) -- CHICAGO -- First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09...
ENHERTU plus Pertuzumab Shows Significant Progress in First-Line Treatment for HER2-Positive Breast Cancer
WILMINGTON, DE — The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab significantly improves progression-free survival (PFS) for patients with HER2-positive metastatic breast cancer when used as a first-line treatment. The findings were presented during a late-breaking session at the 2025 American Society of Clinical Oncology (ASCO) Annua…
Pre-operative THP Achieves Pathological Complete Response in Two-Thirds of
In recent advancements within the realm of breast cancer therapy, the CompassHER2 pCR trial emerges as a beacon of hope by investigating a less intensive neoadjuvant chemotherapy regimen for early-stage HER2-positive breast cancer patients. This groundbreaking Phase II study rigorously evaluates the efficacy of 12 weeks of preoperative treatment consisting solely of the combination known as THP—a regimen integrating trastuzumab and pertuzumab, b…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
